- Home
- ZLAB vs FFBC Comparison
ZLAB vs FFBC Comparison
Compare ZLAB & FFBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- FFBC
- Stock Information
- Founded
- ZLAB 2013
- FFBC 1863
- Country
- ZLAB China
- FFBC United States
- Employees
- ZLAB N/A
- FFBC N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- FFBC Major Banks
- Sector
- ZLAB Health Care
- FFBC Finance
- Exchange
- ZLAB Nasdaq
- FFBC Nasdaq
- Market Cap
- ZLAB 3.4B
- FFBC N/A
- IPO Year
- ZLAB 2017
- FFBC N/A
- Fundamental
- Price
- ZLAB $36.14
- FFBC $24.25
- Analyst Decision
- ZLAB Buy
- FFBC Hold
- Analyst Count
- ZLAB 3
- FFBC 4
- Target Price
- ZLAB $47.37
- FFBC $31.00
- AVG Volume (30 Days)
- ZLAB 1.3M
- FFBC 352.6K
- Earning Date
- ZLAB 05-07-2025
- FFBC 04-24-2025
- Dividend Yield
- ZLAB N/A
- FFBC 3.94%
- EPS Growth
- ZLAB N/A
- FFBC N/A
- EPS
- ZLAB N/A
- FFBC 2.40
- Revenue
- ZLAB $398,988,000.00
- FFBC $756,070,000.00
- Revenue This Year
- ZLAB $45.57
- FFBC $18.64
- Revenue Next Year
- ZLAB $47.91
- FFBC $4.49
- P/E Ratio
- ZLAB N/A
- FFBC $10.16
- Revenue Growth
- ZLAB 49.59
- FFBC N/A
- 52 Week Low
- ZLAB $13.48
- FFBC $20.59
- 52 Week High
- ZLAB $37.99
- FFBC $31.18
- Technical
- Relative Strength Index (RSI)
- ZLAB 64.46
- FFBC 25.99
- Support Level
- ZLAB $34.32
- FFBC $24.08
- Resistance Level
- ZLAB $37.99
- FFBC $25.45
- Average True Range (ATR)
- ZLAB 1.98
- FFBC 0.67
- MACD
- ZLAB 0.02
- FFBC -0.28
- Stochastic Oscillator
- ZLAB 72.51
- FFBC 5.06
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.